DXR

Business Context and Reporting Period

Company: DAXOR CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1997
Business Overview: Daxor operates clinical laboratories (blood and semen banking) and develops medical devices, specifically the Blood Volume Analyzer (BVA). The company's operations are heavily influenced by ongoing litigation with the New York State Department of Health regarding its laboratory licenses.

Key Financial Metrics

Note: Loans Payable includes $1,000,000 in bank loans and approximately $1,578,970 in margin debt secured by marketable securities.

Material Changes vs. Prior Period

• Revenue Composition: Total revenues increased 37.7% for the nine months ended September 30, 1997, compared to the prior year. However, this growth was driven entirely by investment activities. Operating revenues declined 33.4% (from $632,416 to $420,897) due to the revocation of laboratory licenses.
• Profitability: The company reported a net income of $761,263 for the nine months ended September 30, 1997, a significant turnaround from a net loss of $112,731 in the same period in 1996. This improvement is primarily attributed to gains on the sale of securities ($583,741) and dividend income.
• Debt Levels: Loans payable surged from $1,636,067 at December 31, 1996, to $32,588,168 at September 30, 1997. This increase reflects a rise in margin debt used to purchase investments and a new $1,000,000 bank loan.
• Cash Flow: Net cash provided by operating activities was $398,175 for the nine months ended September 30, 1997, compared to $65,540 in the prior year. However, financing activities used $1,757,855, largely due to a $2,353,755 dividend payment.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Product Development: The Blood Volume Analyzer (BVA) received FDA clearance on September 30, 1997. The company is awaiting clearance for the associated kit. Operations at the Oak Ridge manufacturing facility have not yet contributed to earnings.
• Capital Resources: Management states the company has adequate liquid capital to sustain its blood bank and market the BVA. However, expanding blood banking operations on a nationwide basis would require additional capital.
• Dividends: A dividend of $0.50 per share was paid on May 30, 1997, totaling $2,353,755.

Risks and Contingencies

• Legal Proceedings (Critical): The New York State Court of Appeals reversed a lower court decision, ruling that Daxor does not have a property interest in its clinical laboratory and sperm bank licenses. This decision prevents the company from taking new depositors for its blood and semen banks. Daxor is seeking permission to appeal to the U.S. Supreme Court.
• Antitrust Litigation: Daxor has filed a $100 million federal suit (RICO/Antitrust) against the New York Blood Center and Department of Health employees. The outcome is unpredictable but could result in significant recovery of damages.
• Revenue Volatility: Operating revenues remain depressed due to the legal restrictions on laboratory operations. The company relies heavily on investment income and gains from the sale of securities.

Investor Verification Checklist

• License Status: Verify the current status of the appeal to the U.S. Supreme Court regarding the New York State Court of Appeals decision on laboratory licenses.
• Product Commercialization: Confirm the timeline for FDA clearance of the BVA kit and the status of the marketing launch for the Blood Volume Analyzer.
• Debt Structure: Review the terms of the $32.6 million in loans payable, specifically the margin debt secured by marketable securities, to assess liquidity risk if security values decline.
• Legal Exposure: Monitor the progress of the $100 million RICO/Antitrust lawsuit and the class action suit (Yaker v. Department of Health) scheduled for a hearing in December 1997.
• Investment Portfolio: Assess the concentration of the $35.3 million marketable securities portfolio, which primarily consists of utility stocks, and its impact on unrealized gains.